ArticleRheumatology (Oxford, England)2022

Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.

No numbers read from the abstract.

Not cited yet